Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22

Blood Cancer Discovery · Published 2026-07-14 · DOI 10.1158/2643-3230.bcd-26-0186

Authors (33)

Sumithira Vasu, Nathan Denlinger, No-Joon Song, Danielle Elsberry, Qiuhong Zhao, Lianbo Yu, Evandro D. Bezerra, Nicole Szuminski, Dina Schneider, Pradyot Dash, Louisa Wirthlin, Narendranath Epperla, Yazeed Sawalha, Jennifer A. Woyach, Shamama Nishat, Kerry A. Rogers, Seema A. Bhat, Hazem E. Ghoneim, Gregory K. Behbehani, Timothy J. Voorhees, Karilyn Larkin, Adam S. Kittai, Victoria Churchill, Elizabeth George, Margaret Lamb, Dean A. Lee, Wing Keung Chan, Ashley Krull, Rimas J. Orentas, Lynn O’Donnell, Zihai Li, Lapo Alinari, Marcos de Lima

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Vasu, S., Denlinger, N., Song, N., et al. (2026). Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-26-0186

Related articles